Researchers at LSTM, working in partnership with the University of Liverpool and other colleagues, have developed a molecule which has the potential to become the first fully synthetic, one-dose treatment for malaria.
Researchers at LSTM, working in partnership with the University of Liverpool and other colleagues, have developed a molecule which has the potential to become the first fully synthetic, one-dose treatment for malaria.